Abstract: A novel quinolone derivative and methods of its preparation are described in which the novel derivative comprises a diphenyl ether substituent on the nitrogen atom at the 1-position of the main quinolone ring. The novel derivative is shown to have antibacterial and anti-tumor cell activity.

Abstract: The disclosure provides processes for preparing 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile and for preparing sulindac, relating to the field of medicine. The former comprises mixing 6-fluoro-2-methyl-1-indanone, cyanoacetic acid, a first organic solvent and an acetic acid-based catalyst to proceed with a first condensation reaction to give a first condensation reaction solution, which contains 5-fluoro-2-methyl-3-indanacetonitrile; and mixing the first condensation reaction solution, per se, with a base, a second organic solvent and 4-(methylthio)benzaldehyde to proceed with a second condensation reaction to give 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile. The process is a one-pot process without separation of 5-fluoro-2-methyl-3-indanacetonitrile from the solvent, shortening the synthetic route, simplifying the preparation process and improving the 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile yield.

Abstract: Described herein are systems and methods to manage Internet Protocol (IP) address discovery in a software defined networking (SDN) environment. In one example, a manager may generate an IP address discovery configuration and pass the IP address discovery configuration to a controller. Once received, the controller may obtain a discovered list from a hypervisor of one or more IP addresses associated with one or more logical ports and update a realized list for the one or more logical ports based on the discovered list and the IP address discovery configuration.

Abstract: A novel quinolone derivative and methods of its preparation are described in which the novel derivative comprises a diphenyl ether substituent on the nitrogen atom at the 1-position of the main quinolone ring. The novel derivative is shown to have antibacterial and anti-tumor cell activity.

Abstract: Described herein are systems and methods to manage Internet Protocol (IP) address discovery in a software defined networking (SDN) environment. In one example, a manager may generate an IP address discovery configuration and pass the IP address discovery configuration to a controller. Once received, the controller may obtain a discovered list from a hypervisor of one or more IP addresses associated with one or more logical ports and update a realized list for the one or more logical ports based on the discovered list and the IP address discovery configuration.

Abstract: Described herein are systems and methods to manage blacklists and duplicate addresses in software defined networks (SDNs). In one implementation, a method includes, in a control plane and data plane of an SDN environment, obtaining a blacklist for a logical port in the SDN environment. The method further includes deleting realized address bindings in a realized address list for the logical port that match the one or more address bindings in the blacklist and preventing subsequent address bindings that match the one or more address bindings in the blacklist from being added to the realized address list.

Abstract: The present invention provides a method for preparing levobunolol hydrochloride. In the present invention S-1-tert-butyl-epoxy methylamine is subjected to a substitution reaction with 5-hydroxy-1-tetralone, and acidified to obtain the target product levobunolol hydrochloride. The method provided by the present invention greatly improves the regioselectivity of the reaction, avoids the occurrence of side reactions, and effectively improves the yield and optical purity of levobunolol hydrochloride, with the yield being 87.3%, and the ee value being over 99%.

Abstract: The present invention provides a method for preparing a resveratrol compound, and belongs to the technical field of organic synthesis. In the present invention, first alkoxy-substituted benzyl halide, alkoxy-substituted benzaldehyde and a metal catalyst are subjected to oxidative addition and reduction elimination reactions to obtain alkoxy-substituted diphenylethanone; and then the alkoxy-substituted diphenylethanone and a metal catalyst are subjected to reduction, trans elimination and selective debenzylation reactions under a hydrogen atmosphere to obtain the resveratrol compound. In the preparation method of the present invention, the hydrogenation reduction, trans elimination and selective debenzylation reactions can be achieved just by a one-pot process, where the reaction directly obtains a trans olefin, thereby avoiding the formation of a isomer; and also the reaction selectively catalyzes debenzylation to eliminate Lewis acids from the source, and has the advantage of a high yield.

Abstract: The present invention provides a method for preparing levobunolol hydrochloride. In the present invention S-1-tert-butyl-epoxy methylamine is subjected to a substitution reaction with 5-hydroxy-1-tetralone, and acidified to obtain the target product levobunolol hydrochloride. The method provided by the present invention greatly improves the regioselectivity of the reaction, avoids the occurrence of side reactions, and effectively improves the yield and optical purity of levobunolol hydrochloride, with the yield being 87.3%, and the ee value being over 99%.

Abstract: The invention discloses a series of resveratrol-derivative fluorescently labeled molecules and a synthesis method thereof. The fluorescently labeled molecules has a molecular formula as shown in formula (I). The synthesis method includes the steps of adding a certain amount of resveratrol derivative and solvent in a reaction vessel, adding a fluorescent marker as shown in formula (III) and a certain amount of alkali, reacting at 20° C.-60° C. for 2-10 hours, and after the reaction is completed, spin-drying the reaction solvent and performing post-processing to obtain the products.

Abstract: The invention discloses a series of resveratrol-derivative fluorescently labeled molecules and a synthesis method thereof. The fluorescently labeled molecules has a molecular formula as shown in formula (I). The synthesis method includes the steps of adding a certain amount of resveratrol derivative and solvent in a reaction vessel, adding a fluorescent marker as shown in formula (III) and a certain amount of alkali, reacting at 20° C.-60° C. for 2-10 hours, and after the reaction is completed, spin-drying the reaction solvent and performing post-processing to obtain the products.

Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.

Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.

Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer, wherein the TOR kinase inhibitor is a compound of formula (I): and pharmaceutically acceptable salts, clathrates, solvates, stereoisomers, tautomers, metabolites, isotopologues and prodrugs thereof.

Abstract: Provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by a LKB1 and/or AMPK gene or protein loss or mutation.

Abstract: Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1.

Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

Abstract: Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1.

Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.

Abstract: Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1.